TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34187871
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) only
Study: 34188166
Drug: Serum PTX3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum PTX3 above 4.34 ng/mL
Study: 34189178
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg) with loperamide
Study: 34189178
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg) with loperamide
Study: 34189178
Drug: Rifaximin (1650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (1650 mg) with loperamide
Study: 34189178
Drug: Control (pre-antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (pre-antibiotic treatment)
Study: 34189463
Drug: Bevacizumab 5
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg every 2 weeks for 12 weeks
Study: 34190375
Drug: Sunitinib (SUN)
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib (SUN) plus Evofosfamide (EVO) 340 mg/m
Study: 34191201
Drug: Taxane- or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane- or platinum-based chemotherapy
Study: 34191621
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) at 225 mg twice daily
Study: 34192154
Drug: SARS-CoV-2 antibody
Normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 antibody testing using chemiluminescence assays (chemiluminescence immunoassay and electrochemiluminescence)
Study: 34192154
Drug: Antiviral antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral antibody titres
Study: 34192989
Drug: LBSA0103 hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LBSA0103 hyaluronic acid injection
Study: 34193096
Drug: Community-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based intervention consisting of a 20-25 min oral presentation in Urdu and Somali on cervical cancer and screening.
Study: 34193595
Drug: Newer drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer drugs targeting novel blood glucose-lowering pathways
Study: 34193595
Drug: Traditional pharmacologic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional pharmacologic therapies (insulin, metformin, sulfonylureas)
Study: 34193595
Drug: Treatments targeting
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments targeting incretin action, islet transplantation, generation of functional beta cells from stem cells
Study: 34194721
Drug: Levothyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (L-T4) therapy for 12 months
Study: 34195252
Drug: Endobronchial administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endobronchial administration of autologous bone marrow mesenchymal stromal cells (BM-MSCs)
Study: 34195471
Drug: Preoperative preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative preparation with Lugol's Solution (LS)
Study: 34195471
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preoperative preparation with LS)
Study: 34195794
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (LMWH) and/or low-dose aspirin (ASA)
Study: 34195794
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (absence of LMWH/ASA)
Study: 34196037
Drug: Entospletinib in
Normalized name: Entospletinib
DrugBank: Entospletinib (DB12121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entospletinib in combination with obinutuzumab
Study: 34196165
Drug: Tafasitamab (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafasitamab (12 mg/kg intravenously) plus Lenalidomide (25 mg orally)
Study: 39527960
Drug: Betibeglogene autotemcel
Normalized name: betibeglogene autotemcel
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betibeglogene autotemcel (beti-cel) gene therapy
Study: 34201806
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin (1 mg) plus zinc (10 mg) supplementation
Study: 34206826
Drug: Cantrixil (TRX-E-002-1);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cantrixil (TRX-E-002-1); specific dosage and duration not mentioned.
Study: 34208432
Drug: Long-term therapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term therapy with Statins and Acetyl Salicylic Acid
Study: 34210826
Drug: SENTI-101 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: SENTI-101 (a preparation of bone marrow-derived mesenchymal stromal cells engineered to express IL12 and IL21)
Study: 34210826
Drug: mSENTI-101 co-administered
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mSENTI-101 co-administered with checkpoint inhibitors
Study: 34211280
Drug: High-dosage inhaled
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage inhaled corticosteroids with additional controllers (HD ICS+)
Study: 34211773
Drug: SBRT 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBRT 30 to 50 Gy in 5 fractions (median dose 40 Gy)
Study: 34212814
Drug: Inappropriate medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate medication stopping
Study: 34213732
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg lipegfilgrastim (single SC injection)
Study: 34213962
Drug: Rivastigmine treatment
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine treatment for memory impairment after TBI
Study: 34215024
Drug: NTLA-2001 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTLA-2001 (0.1 mg/kg)
Study: 34215024
Drug: NTLA-2001 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTLA-2001 (0.3 mg/kg)
Study: 34215319
Drug: SB cell
Normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB cell treatment (1 × 10)
Study: 34215319
Drug: SB cell
Normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB cell treatment
Study: 34215323
Drug: Mentalization-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based treatment for conduct disorder (MBT-CD)
Study: 34215684
Drug: Voluntary daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluntary daily noise monitoring intervention
Study: 34215909
Drug: Asfotase alfa
Normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asfotase alfa treatment
Study: 34216069
Drug: CRT-D therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-D therapy
Study: 34216069
Drug: ICD implant
Normalized name: ICDMT
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ICD implant
Study: 34216189
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy with corticosteroids and statins
Study: 34216247
Drug: Budigalimab 250
Normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budigalimab 250 mg intravenously Q2W
Study: 34216247
Drug: Budigalimab 500
Normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budigalimab 500 mg intravenously Q4W
Study: 34216247
Drug: Budigalimab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budigalimab (both dosing regimens)
Study: 34217109
Drug: Novel effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel effective therapies targeting key signaling pathways in PAH
Study: 34217426
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral PrEP (coformulated tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg)
Study: 34218284
Drug: S antibodies
Normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: S antibodies
Study: 34218284
Drug: N antibodies
Normalized name: digoxin antibodies Fab fragments
Approvals — FDA: no, EMA: no, PMDA: no
Description: N antibodies
Study: 34222719
Drug: IONIS-AGT-L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IONIS-AGT-L
Study: 34222761
Drug: Monthly review
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly review meetings with staff and supervisors
Study: 34222848
Drug: MVC-COV1901 5
Normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVC-COV1901 5 μg
Study: 34222848
Drug: MVC-COV1901 15
Normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVC-COV1901 15 μg
Study: 34222848
Drug: MVC-COV1901 25
Normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVC-COV1901 25 μg
Study: 34222849
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate and emtricitabine (2 pills on day 1 followed by 1 pill per day on days 2-7)
Study: 34222847
Drug: Nitazoxanide (NTZ)
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide (NTZ) 600 mg BID for seven days
Study: 34223347
Drug: Vasopressin and
Normalized name: Vasopressin and analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin and Methylprednisolone (40 mg methylprednisolone and 20 IU vasopressin, with additional doses of vasopressin after each adrenaline dose for a maximum of four doses)
Study: 34223403
Drug: Glucose metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose metabolism via glycolysis
Study: 34223403
Drug: Glucose metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose metabolism
Study: 34223402
Drug: RH5.1 recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: RH5.1 recombinant protein vaccine
Study: 34224261
Drug: Infusion Centers
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion Centers (ICs)
Study: 34224432
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with BPA
Study: 34224432
Drug: BPA alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPA alone or in combination with PEA or medical therapy
Study: 34529762
Drug: BNT162b2 vaccine
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccine (2 doses)
Study: 34224684
Drug: XC001 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: XC001 gene therapy
Study: 34226282
Drug: Control saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control saline infusion (SC)
Study: 34227124
Drug: Hydroxyurea (hydroxycarbamide)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing starting at predicted maximum tolerated dose (MTD)
Study: 34227790
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (aerobic and resistance training) for 12 weeks, twice weekly
Study: 34227849
Drug: Referral processes
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral processes to clinic-community partnership programs for childhood obesity treatment
Study: 34229186
Drug: Standardized antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized antidepressant treatment protocol for 16 weeks
Study: 34229268
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 200 mg PM
Study: 34229268
Drug: Three daily
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three daily dose of 67 mg PM
Study: 34229325
Drug: Support to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Support to access downstream treatment
Study: 34229330
Drug: Nonnucleoside reverse
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonnucleoside reverse transcriptase inhibitor resistance
Study: 34229330
Drug: Nucleoside reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside reverse transcriptase inhibitor resistance
Study: 34230007
Drug: MDM2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MDM2 inhibitor ALRN-6924
Study: 34230007
Drug: MDM2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MDM2 inhibitors
Study: 34232223
Drug: Proprotein convertase
Normalized name: Proprotein convertase 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprotein convertase subtilisin/kexin 9 inhibitors
Study: 34232493
Drug: Nebulized glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized glycopyrrolate (GLY) 25 µg
Study: 34232694
Drug: Standard-Dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-Dose CT
Study: 34233259
Drug: Key radiomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Key radiomic features before and after neoadjuvant chemotherapy
Study: 34233458
Drug: Glucose derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose derivative treatment
Study: 34233992
Drug: Treatment pathways
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment pathways for knee OA
Study: 34235085
Drug: EphA2-redirected CAR
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EphA2-redirected CAR T-cells (starting dosage 1×10)
Study: 34236298
Drug: Training in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training in opioid treatment as peer recovery support service interventionists
Study: 34236401
Drug: PLX9486 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLX9486 at 500 mg or less
Study: 34236401
Drug: PLX9486 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLX9486 at 1000 mg
Study: 34236401
Drug: PLX9486 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLX9486 at 500 mg or less with sunitinib
Study: 34236401
Drug: PLX9486 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLX9486 and sunitinib combination (25 or 37.5 mg)
Study: 34236525
Drug: Lying position
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lying position (LyP) for 30 minutes daily during the first 7 days of hospitalization
Study: 34236995
Drug: Pfizer-BioNTech COVID-19
Normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer-BioNTech COVID-19 vaccine (first dose)
Study: 34236995
Drug: Pfizer-BioNTech COVID-19
Normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer-BioNTech COVID-19 vaccine (second dose)
Study: 34236995
Drug: Pfizer-BioNTech COVID-19
Normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer-BioNTech COVID-19 vaccine (both doses)
Study: 34237031
Drug: Selpercatinib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selpercatinib combined with 131I therapy
Study: 34240339
Drug: Dasatinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (60 or 80 mg/m2)
Study: 34241781
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 21 days until progressive disease, unacceptable adverse event, or completion of 24 months of treatment.
Study: 34242221
Drug: Subcutaneous adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous adipose tissue (SAT) index
Study: 34242388
Drug: Panobinostat (PANO)
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat (PANO) 5 mg orally 3 times a week for 26 weeks, starting on day -5, in combination with tacrolimus and sirolimus.
Study: 34243799
Drug: Protamine administration
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine administration
Study: 34244298
Drug: Multiplexed engineering
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiplexed engineering approach using lentiviruses for CAR T-cell immunotherapy
Study: 34244325
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intravenous doses of phosphorus
Study: 34246328
Drug: Nomograms developed
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomograms developed from predictors including time since initial diagnosis, chemotherapy status, baseline haemoglobin concentration.
Study: 34246461
Drug: Remimazolam 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam 0.1 mg/kg (single bolus) in hepatic impairment trial
Study: 37942930
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (SXB) treatment
Study: 34248840
Drug: Hyperinsulinemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic clamp with induced normoglycemia (4.5 ± 0.07 mmol/L for 1 hour) in T2D
Study: 34248841
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (ACEi) therapies in T2D subjects
Study: 34249763
Drug: Intravitreal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravitreal methotrexate (MTX, 400 μg, 0.1 mL) injections for 1 year (total 16 injections) and six cycles of rituximab (375 mg/m2).
Study: 34250266
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of tranexamic acid
Study: 34250266
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of tranexamic acid
Study: 34250266
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of tranexamic acid
Study: 34250553
Drug: Seribantumab 40/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seribantumab 40/20 mg/kg (loading dose followed by maintenance dose)
Study: 34250553
Drug: Seribantumab (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seribantumab (various doses: 3.2, 6, 10, 15, or 20 mg/kg weekly)
Study: 34251649
Drug: Aprocitentan (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan (up to 600 mg single dose and 100 mg once daily at multiple doses)
Study: 34252125
Drug: Sequential organ
Normalized name: argan oil
DrugBank: Argan oil (DB14310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential organ failure assessment (SOFA) score
Study: 34253172
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg/day until disease progression or other withdrawal criteria
Study: 34253376
Drug: Locoregional melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locoregional melphalan chemotherapy (hyperthermic isolated limb perfusion)
Study: 34253376
Drug: Locoregional melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locoregional melphalan chemotherapy (isolated limb infusion)
Study: 34253376
Drug: Locoregional melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locoregional melphalan chemotherapy
Study: 34253577
Drug: Zanubrutinib 160
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 160 mg twice daily until disease progression or unacceptable toxicity
Study: 34253587
Drug: Donor-specific HLA
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor-specific HLA antibody (DSA) positivity in NR biopsies
Study: 34253733
Drug: AAV2-hAADC delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV2-hAADC delivered via convection-enhanced delivery (CED) to the bilateral substantia nigra (SN) and ventral tegmental area (VTA) with a total infusion volume of 80 µL per hemisphere.
Study: 34253928
Drug: HER2-specific CAR
Normalized name: RHUMAB HER2
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HER2-specific CAR T cells via locoregional infusion
Study: 34255063
Drug: Iodine-containing supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-containing supplement initiated prepregnancy and continued through pregnancy
Study: 34255063
Drug: No use
Approvals — FDA: no, EMA: no, PMDA: no
Description: No use of supplement
Study: 34255078
Drug: Phytoglycogen (PHY)
Normalized name: SUNSCREEN 30-50/PHY BLOCK/PABA-F LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoglycogen (PHY) at 0.5 g·min-1
Study: 34255078
Drug: Phytoglycogen (PHY)
Normalized name: SUNSCREEN 30-50/PHY BLOCK/PABA-F LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoglycogen (PHY) at 1.0 g·min-1
Study: 34255078
Drug: Phytoglycogen (PHY)
Normalized name: SUNSCREEN 30-50/PHY BLOCK/PABA-F LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoglycogen (PHY) at 1.5 g·min-1